Ad­vances both ma­jor and mi­cro­scopic

The Jewish Chronicle - - JC SPECIAL - BY GINA BEN­JAMIN

AN IS­RAELI treat­ment t o pro­mote the heal­ing of chronic wounds is now a v a i l a b l e i n Lon­don at the newly opened Lon­don Wound Clinic i n Har­ley Street. The clinic spe­cialises in the treat­ment and man­age­ment of chronic wounds, such as leg and foot ul­cers or pres­sure sores. Foot ul­cers oc­cur in 15 per cent of di­a­betic pa­tients, ow­ing to the as­so­ci­ated loss of sen­sa­tion in the lower limbs, while pres­sure sores af­fect up to 20 per cent of hos­pi­tal in­pa­tients.

This is the first spe­cial­ist clinic in the UK to of­fer the Is­raeli BRH ther­apy, which uses a com­bi­na­tion of elec­tros­tim­u­la­tion and l o w- f r e q u e n c y ul­tra­sound. The Lon­donWound Clinic and sur­geon Jeremy Crane pain­less, non-in­va­sive tech­nol­ogy aids heal­ing by in­creas­ing blood flow within wounds. On the team at the Lon­don Wound Clinic are Jeremy Crane, con­sul­tant vas­cu­lar and trans­plant sur­geon (Im­pe­rial Col­lege Healthcare NHS Trust); Lynne Hudgell, se­nior lec­turer in tis­sue vi­a­bil­ity; and Dr Miles Boy­den, GP.

Tina Cham­bers, vice chair of the Tis­sue Vi­a­bil­ity So­ci­ety, says: “An open wound on the foot or leg can lead to in­fec­tion, which can at best cause de­lay in heal­ing and at worst re­sult in am­pu­ta­tion and death. With the num­ber of di­a­betic pa­tients in­creas­ing, the num­ber of peo­ple with foot ul­cer­a­tion will grow, in­creas­ing the bur­den on the health ser­vice. Any tech­nol­ogy that can as­sist in the heal­ing of these chronic wounds and thereby de­crease the num­bers re­quir­ing treat­ment will be ben­e­fi­cial, not only to the pa­tient them­selves, but the healthcare sys­tem too. “The BRH-A2 ther­apy com­bines two known t e c h n o l o g i e s i n wound care, and early signs are that it can help some di­a­betic foot wounds and leg ul­cers heal faster.

“This is bene f i c i a l , a s t h e quicker the wound closes, the speed­ier the re­duc­tion in the as­so­ci­ated risk of


Cen­trasight’s mi­nus­cule te­le­scope re­stores cen­tral vi­sion


Age-re­lated mac­u­lar de­gen­er­a­tion (AMD) is the most com­mon cause of blind­ness in peo­ple aged 60 and over in the UK, ex­pe­ri­enced by more than 600,000 peo­ple. It af­fects the cen­tral vi­sion which we use to recog­nise faces and see ob­jects in front of us.

Un­til the re­cent de­vel­op­ment of a treat­ment called Cen­traSight, there were few op­tions for peo­ple with end­stage AMD. Spire Bushey Hos­pi­tal’s oph­thalmic unit is the latest cen­tre in the UK to of­fer Cen­traSight to those with AMD. The treat­ment uses a tiny te­le­scope im­plant, smaller than a pea, which mag­ni­fies im­ages about three times. The en­larged im­ages are pro­jected on to the healthy part of the retina, mak­ing it pos­si­ble to use the cen­tral vi­sion again.

The pro­ce­dure is pain­less and takes

Newspapers in English

Newspapers from UK

© PressReader. All rights reserved.